Bendamustine and Rituximab As First-Line Treatment for Symptomatic Splenic Marginal Zone Lymphoma: Long-Term Outcome and Impact of Early Unmeasurable Minimal Residual Disease Attainment from the BRISMA/IELSG36 Phase II StudyEmilio Iannitto,Simone Ferrero,Come Bommier,Daniela Drandi,Martina Ferrante,Krimo Bouabdallah,Sylvain Carras,Guido Gini,Vincent Camus,Salvatrice Mancuso,Luigi Marcheselli,Angela Ferrari,Michele Merli,Benoit Tessoulin,Caterina Stelitano,Kheira Beldjord,Giovanni Roti,Fabrice Jardin,Barbara Castagnari,Francesca Palombi,Lucile Baseggio,Alexandra Traverse-Glehen,Claudio Tripodo,Anna Marina Liberati,Margherita Parolini,Sara Usai,Caterina Patti,Massimo Federico,Maurizio Musso,Marco Ladetto,Emanuele Zucca,Catherine ThieblemontHaematologica(2024)Cited 0|Views44AI Read ScienceMust-Reading TreeExampleGenerate MRT to find the research sequence of this paperChat PaperSummary is being generated by the instructions you defined